Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
122
days
Comparison of RNA-seq and microarray-based models for clinical endpoint prediction
Authors
Wenqian Zhang; Ying Yu; Falk Hertwig; Jean Thierry-Mieg; Wenwei Zhang; Danielle Thierry-Mieg; Jian Wang; Cesare Furlanello; Viswanath Devanarayan; Jie Cheng; Youping Deng; Barbara Hero; Huixiao Hong; Meiwen Jia; Li Li; Simon M Lin; Yuri Nikolsky; André Oberthuer; Tao Qing; Zhenqiang Su; Ruth Volland; Charles Wang; May D. Wang; Junmei Ai; Davide Albanese; Shahab Asgharzadeh; Smadar Avigad; Wenjun Bao; Marina Bessarabova; Murray H. Brilliant; Benedikt Brors; Marco Chierici; Tzu-Ming Chu; Jibin Zhang; Richard G. Grundy; Min Max He; Scott Hebbring; Howard L. Kaufman; Samir Lababidi; Lee J. Lancashire; Yan Li; Xin X. Lu; Heng Luo; Xiwen Ma; Baitang Ning; Rosa Noguera; Martin Peifer; John H. Phan; Frederik Roels; Carolina Rosswog; Susan Shao; Jie Shen; Jessica Theissen; Gian Paolo Tonini; Jo Vandesompele; Po-Yen Wu; Wenzhong Xiao; Joshua Xu; Weihong Xu; Jiekun Xuan; Yong Yang; Zhan Ye; Zirui Dong; Ke K. Zhang; Ye Yin; Chen Zhao; Yuanting Zheng; Russell D. Wolfinger; Tieliu Shi; Linda H. Malkas; Frank Berthold; Jun Wang; Weida Tong; Leming Shi; Zhiyu Peng; Matthias FischerShow moreShow less
Affiliations
1. BGI-Shenzhen, Main Building, Bei Shan Industrial Zone, Shenzhen, China; 2. Collaborative Innovation Center for Genetics and Development, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences and School of Pharmacy, Fudan University, Shanghai, China; 3. Department of Pediatric Oncology and Hematology, University Children’s Hospital of Cologne, Cologne, Germany; 4. University of Cologne, Center for Molecular Medicine (CMMC), Medical Faculty, Cologne, Germany; 5. NIH/NCBI, Bethesda, USA; 6. Eli Lilly and Company Research Informatics, Lilly Corporate Center, Indianapolis, USA; 7. Fondazione Bruno Kessler (FBK), Trento Povo, Italy; 8. AbbVie Inc., Global Pharmaceutical R&D, Souderton, USA; 9. GlaxoSmithKline, Discovery Analytics, Collegeville, USA; 10. Department of Internal Medicine, Rush University Cancer Center, Chicago, USA; 11. National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, USA; 12. SAS Institute Inc., Cary, USA; 13. Marshfield Clinic Research Foundation, Biomedical Informatics Research Center, Marshfield, USA; 14. Thomson Reuters IP & Science, Carlsbad, USA; 15. Center for Genomics and Division of Microbiology & Molecular Genetics, School of Medicine, Loma Linda University, Loma Linda, USA; 16. Department of Biomedical Engineering, GeorgiaTech and Emory University, Atlanta, USA; 17. Fondazione Edmund Mach, CRI-CBC, San Michele all’Adige, Italy; 18. Children’s Hospital Los Angeles, Los Angeles, USA; 19. Department of Pediatric Hematology-Oncology, Molecular Oncology, Felsenstein Medical Research Center, Schneider Children’s Medical Center of Israel, Petach Tikva, Israel; 20. Marshfield Clinic Research Foundation, Center of Human Genetics, Marshfield, USA; 21. Department of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany; 22. University of Nottingham, Children’s Brain Tumour Research Centre, Queen’s Medical Centre, University of Nottingham, Nottingham, UK; 23. Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, WOC1 RM400S, HFM-210, Rockville, USA; 24. AbbVie Inc., Global Pharmaceutical Research and Development, North Chicago, USA; 25. University of Arkansas at Little Rock, UALR/UAMS Joint Bioinformatics Graduate Program, Little Rock, USA; 26. Eli Lilly and Company, Discovery Statistics, Lilly Corporate Center, Indianapolis, USA; 27. Department of Pathology, University of Valencia, Medical School, Valencia, Spain; 28. Department of Translational Genomics, University of Cologne, Cologne, Germany; 29. Neuroblastoma Laboratory, Onco/Hematology Laboratory, SDB Department, University of Padua, Pediatric Research Institute, Padua, Italy; 30. Department of Pediatrics and Genetics, Ghent University, Center for Medical Genetics, Ghent University, Ghent, Belgium; 31. Georgia Institute of Technology, School of Electrical and Computer Engineering, Atlanta, USA; 32. Harvard Medical School, Massachusetts General Hospital, Boston, USA; 33. Stanford University, Stanford Genome Technology Center, Palo Alto, USA; 34. Department of Pathology, University of North Dakota School of Medicine, Grand Forks, USA; 35. East China Normal University, Center for Bioinformatics and Computational Biology, Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, Shanghai, China; 36. Department of Molecular & Cellular Biology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, USA; 37. Department of Biology, University of Copenhagen, Copenhagen, Denmark; 38. King Abdulaziz University, Jeddah, Saudi Arabia; 39. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; 40. BGI-Guangzhou, Guangzhou Higher Education Mega Center, Guangzhou, ChinaShow moreShow less
46
days
FOXM1 binds directly to non-consensus sequences in the human genome
Authors
Deborah A. Sanders; Michael V. Gormally; Giovanni Marsico; Dario Beraldi; David Tannahill; Shankar BalasubramanianShow moreShow less
Affiliations
1. Cancer Research UK, Cambridge Research Institute, Cambridge, UK; 2. Present address: Domainex, Cambridge, UK; 3. Department of Chemistry, University of Cambridge, Cambridge, UK; 4. School of Clinical Medicine, The University of Cambridge, Cambridge, UKShow moreShow less
91
days
Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells
Authors
Kyu-Tae Kim; Hye Won Lee; Hae-Ock Lee; Sang Cheol Kim; Yun Jee Seo; Woosung Chung; Hye Hyeon Eum; Do-Hyun Nam; Junhyong Kim; Kyeung Min Joo; Woong-Yang ParkShow moreShow less
Affiliations
1. Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea; 2. Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, South Korea; 3. Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, South Korea; 4. Department of Urology, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea; 5. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea; 6. Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Seoul, South Korea; 7. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea; 8. Department of Biology, University of Pennsylvania, Philadelphia, USA; 9. Penn Program in Single Cell Biology, University of Pennsylvania, Philadelphia, USA; 10. Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Seoul, South KoreaShow moreShow less
128
days
Extensive rewiring of epithelial-stromal co-expression networks in breast cancer
Authors
Eun-Yeong Oh; Stephen M Christensen; Sindhu Ghanta; Jong Cheol Jeong; Octavian Bucur; Benjamin Glass; Laleh Montaser-Kouhsari; Nicholas W Knoblauch; Nicholas Bertos; Sadiq MI Saleh; Benjamin Haibe-Kains; Morag Park; Andrew H BeckShow moreShow less
Affiliations
1. Cancer Research Institute, Beth Israel Deaconess Cancer Center, Boston, USA; 2. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, USA; 3. Harvard Medical School, Boston, USA; 4. Goodman Cancer Research Centre, McGill University, Montreal, Canada; 5. Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; 6. Department of Medical Biophysics, University of Toronto, Toronto, CanadaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days